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Abstract
Aims—Multidrug resistance (MDR) mediated by overexpression of drug efflux transporters such
as P-glycoprotein (P-gp), is a major problem, limiting successful chemotherapy of breast cancer.
The use of siRNA to inhibit P-gp expression in MDR tumors is an attractive strategy to improve
the effectiveness of anticancer drugs.
Method—We have synthesized a novel conjugate between a phospholipid
(dioleoylphosphatidylethanolamine) and polyethylenimine (PEI) for siRNA delivery, for the
purpose of silencing P-gp to overcome doxorubicin resistance in MCF-7 human breast cancer
cells.
Results—The dioleoylphosphatidylethanolamine-PEI conjugate enhanced the transfection
efficacy of low-molecular-weight PEI, which was otherwise totally ineffective. In addition, the
polyethylene glycol/lipid coating of the new complexes gave rise to small micelle-like
nanoparticles with improved biocompatibility properties. Both coated and noncoated formulations
delivered P-gp-specific siRNA to MDR cells.
Discussion—The combination of doxorubicin and P-gp silencing formulations led to a twofold
increase of doxorubicin uptake and a significant improvement of the therapeutic effect of
doxorubicin in resistant cells.
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Multidrug resistance (MDR) is a major problem, limiting the treatment of breast cancer.
Several molecular mechanisms are involved in the development of a drug-resistant
phenotype [1]. One of the most studied resistance mechanisms is the reduction of
intracellular drug concentration by transporter proteins that pump drugs out of cells before
they reach the site of action. Many of these transporters are members of the ATP-binding
cassette transmembrane protein super-family, including P-glycoprotein (P-gp), MDR
protein-1 (MRP-1) and breast cancer resistant protein. P-gp was the first described and is the
best characterized to date.
P-gp encoded by the MDR-1 gene is a 170 kDa plasma membrane protein with 12
transmembrane domains and two ATP-binding domains. P-gp uses ATP energy to transport
drugs and other xenobiotics from the intracellular to the extracellular compartment, although
it may also interact with transmembrane substrates [2]. The localization of P-gp in normal
tissues suggests that this transporter has the physiological function of detoxification and
excretion of xenobiotics [3,4]. In tumor tissue, intrinsic or induced overexpression of P-gp
after exposure to chemotherapy agents has been extensively investigated as one primary
reason for chemotherapy failure in different MDR cancer types [5–8]. Regarding breast
cancer, an induced expression of P-gp in cancer cells by exposure to anticancer drugs was
detected in 52% of chemotherapy-treated patients [9]. P-gp expression has also been related
to a significant increase in doxorubicin and taxol resistance of breast tumors, regardless of
prior treatment [10].
Apart from chemical P-gp inhibitors [11,12], the silencing of the MDR-1 gene with siRNA
could become a powerful tool to restore chemotherapy sensitivity in MDR cancer cells
[13,14]. siRNA duplexes are short nucleotide molecules of approximately 21–25 base pairs
that can trigger silencing of homologous gene expression by inducing degradation of the
complementary mRNA [15]. Clear advantages of the siRNA approach compared with
chemical inhibitors are its reduced toxicity towards nonspecific tissues and its high
specificity. The main problems with siRNA include its poor in vivo stability (rapid
degradation in plasma and cellular cytoplasm) and poor cellular uptake that have limited its
clinical application to date.
Polyethylenimine (PEI) is widely used for nucleic acid delivery, including siRNA delivery
[16–19]. The high charge density of PEI permits the condensation of nucleic acids by
electrostatic interactions into dense particles (complexes) that protect the genetic material
from enzymatic degradation and promote their cellular uptake by absorptive endocytosis.
Additionally, PEI has an intrinsic endosomal escape mechanism known as the ‘proton
sponge’ effect, which causes osmotic swelling and rupture of the endosome membrane,
which then triggers the release of PEI complexes into the cytosol [20]. In general, high-
molecular-weight PEIs provide high transfection efficiency but also have high toxicity due
to nonspecific interactions with blood components and nontarget sites. By contrast, low-
molecular-weight PEIs are more biocompatible but much less efficient. In order to achieve a
more favorable balance between the efficacy and toxicity of PEI, different strategies have
been suggested, including the conjugation with lipid or polyethylene glycol (PEG) moieties.
Lipid substitution of cationic polymers, mainly grafting fatty acid or cholesterol, has been
reported to improve the stability and uptake of the complexes, most probably because the
lipid residues provide a better interaction with the cellular membrane [21–25]. Noncovalent
association of PEI complexes with either PEGylated or non-PEGylated liposomal
formulations has also led to nontoxic and efficient siRNA in vitro delivery [26,27].
In previous studies, we have demonstrated that phosphatidylcholine (PC)-modified PEI
effectively condensed and protected siRNA or plasmid DNA from enzymatic degradation
and improved its uptake by cancer cells. We have also reported on micelle-like nanoparticles
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(MNPs), that is, phospholipid–PEI complexes coated with a PEG–lipid/lipid mix [28,29].
MNPs showed similar transfection efficacy to that of PEI but with improved
biocompatibility properties, such as the absence of in vitro or in vivo acute toxicity and
prolonged blood circulation [28].
In this study, the positive results obtained with PC-modified PEI and MNPs have been
further improved by grafting a different phospholipid, dioleoylphosphatidylethanolamine
(DOPE), to the backbone of PEI. Additionally, the potential therapeutic application of this
novel lipid-PEI carrier has been confirmed by combining P-gp silencing siRNA delivery
with doxorubicin treatment to overcome the drug resistance in human breast cancer MCF-7
cells.
Materials & methods
Materials
All materials were purchased from Sigma-Aldrich (MO, USA), unless otherwise stated.
Branched PEI with a molecular weight of 1.8 kDa was purchased from Polysciences, Inc.
(PA, USA). 1-Palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC), 1,2-disrearoyl-sn-
glycero-3-phosphoethanolamine-N-[methoxy (PEG)-2000] (PEG-PE), cholesterol, and 1,2-
dioleoyl-sn-glycero-3-phosphoethanolamine-N-(glutaryl) were purchased from Avanti Polar
Lipids (AL, USA). All siRNA duplexes were purchased from Dharmacon (CO, USA).
Namely, siRNA targeting green fluorescent protein (GFP-siRNA): 5´-
AUGAACUUCAGGGUCAGCUdTdT-3´ (sense) [30], siRNA targeting MDR-1
(siMDR-1): 5´-GGAAAAGAAACCAACUGUCdTdT-3´ (sense) [31], and a non-targeting
control siRNA, (siNegative): 5´-AGUACUGCUUACGAUACGGdTdT-3´ (sense).
Fluorescein isothiocyanate-labeled P-gp antibody (UIC2) was purchased from Abcam (MA,
USA). Lipofectamine™ 2000 Reagent was purchased from Invitrogen (CA, USA). The
CellTiter-Blue® Cell Viability Assay was purchased from Promega (WI, USA). Cells of the
c166 cell line (mouse yolk sac embryo) stably transfected with a plasmid reporter vector,
pEGFP-N1, encoding for the enhanced GFP, were obtained from the American Type
Culture Collection (VA, USA). DMEM was supplemented with 10% fetal bovine serum
from Atlanta Biologicals (GA, USA) and 0.2 mg/ml of Geneticin (G-418, Invitrogen). The
wild-type (sensitive) and doxorubicin-resistant MCF-7 human breast adenocarcinoma cells
were kindly provided by T Minko (The State University of New Jersey, NJ, USA). The
resistant MCF-7 phenotype has been previously characterized as overexpressing the MDR-1
gene [32]. Both MCF-7 cell lines were grown at 37°C under 5% CO2 in DMEM
supplemented with 10% fetal bovine serum and penicillin (100 units/ml) and streptomycin
(100 µg/ml). DMEM and penicillin/streptomycin stock solutions were purchased from
Cellgro (VA, USA). Heat-inactivated fetal bovine serum was purchased from Atlanta
Biologicals (GA, USA). Nuclease-free water was purchased from Qiagen (MD, USA).
Methods
Synthesis of DOPE–PEI conjugates—The DOPE-PEI conjugate was synthesized from
PEI 1.8 kDa and the glutaryl-modified phospholipid 1, 2-dioleoyl-sn-glycero-3-
phosphoethanolamine. Briefly, the glutaryl-modified phospholipid 1, 2-dioleoyl-sn-
glycero-3-phosphoethanolamine (5.5 µM) in chloroform was activated with N-(3-
dimethylaminopropyl)-N’-ethylcarbodiimide HCl and N-hydroxysuccinimide followed by
addition of PEI 1.8 kDa (5.5 µM). The mixture was incubated with 4 µl of triethylamine at
room temperature for 24 h with stirring. The chloroform was removed under nitrogen gas
and the residue was suspended with 1 ml of distilled water. The product was purified by
dialysis (molecular weight cut-off: 2000 Da) against distilled water and lyophilized. The
solid product (5–10 mg) was dissolved in chloroform-d (1 ml) and characterized by 1H-
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nuclear magnetic resonance using Varian 500 mHz spectroscopy. Analysis of spectra from
peak integration indicated the ratio of DOPE:PEI as 1:1.
Preparation of DOPE-PEI/siRNA complexes—Complexes were prepared by mixing a
fixed amount of siRNA and varying amounts of DOPE-PEI that were separately diluted in
equal volumes of 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid-buffered glucose
solution, (pH 7.4; nuclease-free). The siRNA solution was transferred to the polymer
solution, mixed by pipetting and incubated for 15 min. The polymer/siRNA ratio was
expressed as the PEI nitrogen/nucleic acid phosphate (N/P) ratio, and calculated assuming
that each repeating unit of PEI containing one amine corresponds to 43 g/mol and that 316
g/mol corresponds to each repeating unit of siRNA containing one phosphate.
Gel retardation studies—For gel retardation studies, complexes containing 750 ng of
siRNA with varying amounts of DOPE-PEI or PEI 1.8 kDa in 4-(2-hydroxyethyl)-1-
piperazineethanesulfonic acid-buffered glucose solution were subjected to electrophoresis
on a 0.8% agarose gel, using an E-Gel electrophoresis system (Invitrogen Life
Technologies) and evaluated under UV light.
Ethidium bromide exclusion assay—The binding of DOPE-PEI to siRNA was
examined by the quenching method based on the use of ethidium bromide (EtBr). The
experiments were carried out by measuring the fluorescence intensity of complexes prepared
from siRNA (5 µg/ml) with EtBr intercalated at a molar ratio of 2:1 (siRNA:EtBr) as
increasing amounts of DOPE-PEI or PEI 1.8 kDa were added. The fluorescence was
measured using a 96-well plate reader (Multiscan MCC/340) at the excitation and emission
wavelengths of 540 and 580 nm, respectively. The relative fluorescence values were
determined as follows: Fr = (Fm–Fe) × 100/ (Fo–Fe), where Fr is the relative fluorescence,
Fm is the measured fluorescence, Fe is the fluorescence of EtBr in the absence of siRNA
and Fo is the initial fluorescence in the absence of the polycation.
Stability of siRNA in DOPE-PEI complexes against RNase digestion—Nuclease
resistance of the siRNA in DOPE-PEI complexes was determined by the treatment of the
samples with 1 U of RNase III/µg siRNA for 2 h at 37°C. Complexes were disassembled by
adding heparin (40 U/µg siRNA) and analyzed by agarose gel electrophoresis. The integrity
of siRNA in complexes was compared with that of naked siRNA.
Preparation of DOPE-PEI-based MNPs—The MNPs were assembled with DOPE-
PEI:POPC:cholesterol:PEG-PE (4:3:3:0.3 mol/mol) and siRNA. First, 32 µg DOPE-PEI
(21.7 µg as PEI) and 10 µg siRNA corresponding to an N/P ratio of 16 were diluted
separately in 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid-buffered glucose solution
and mixed to a final volume of 200 µl. A dry lipid film was prepared from the mixture of
POPC, cholesterol and PEG-PE (6.8, 3.5 and 2.5 µg; 3:3:0.3 mol/mol). The lipid film was
hydrated with the preformed DOPE-PEI complexes and incubated for 1 h at room
temperature.
Particle size & zeta-potential measurements—The particle size and zeta potential of
the formulations were measured by quasi-electric light scattering using a zeta plus particle
analyzer (Brookhaven Instruments Corp, CA, USA). Scattered light was detected at 25°C at
an angle of 90°. Samples (100 µl) of complexes and MNPs were diluted in 1.7 ml of
nuclease-free water and measured immediately after preparation.
GFP silencing—In vitro GFP silencing experiments were performed in stably transfected
c166 GFP cells using GFP-siRNA. A nontargeting control duplex (negative-siRNA) was
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used as a non-specific control siRNA. Cells were seeded 24 h prior to transfection in 12-well
plates at a density of 5 × 104 per well and complete medium was replaced with fresh serum-
free medium. DOPE-PEI complexes at varying N/P ratios were added to cells to yield a final
siRNA concentration of 100 nM. After 4 h of incubation, the complexes were removed and
fresh complete media was added. The cells were further incubated for 48 h. Thereafter, the
cells were washed, detached by trypsinization, and GFP downregulation was analyzed by
flow cytometry. In the second set of experiments, c166 GFP cells were treated, under the
above conditions, with free siRNA or siRNA formulated in PEI 1.8 kDa complexes, DOPE-
PEI complexes or MNPs. All formulations were prepared at a N/P ratio of 16.
Lipofectamine 2000 was used as a positive control according to the manufacturer’s protocol.
P-gp silencing—For P-gp silencing experiments, MCF-7 resistant cells were seeded in
12-well plates at a density of 5 × 104 per well. After 24 h, the cells were treated with DOPE-
PEI complexes, MNPs or PEI 1.8 kDa complexes containing either siMDR-1 or a scramble
siRNA (siNegative). All formulations were prepared at an N/P ratio of 16. Lipofectamine
2000 was used as a positive control. The final concentration of siRNA was 100 nM. After 4
h of incubation, the treatments were removed and cells were reincubated for 48 h. The cells
were washed, detached by mechanical scrapping and resuspended in bovine serum albumin
0.5%. The cell suspensions were incubated with a fluorescein isothiocyanate-labeled
antibody against P-gp at 4°C. After 40 min of incubation, the cells were washed with 0.5%
bovine serum albumin and analyzed by flow cytometry.
Intracellular doxorubicin accumulation—MCF-7 resistant and sensitive cells were
seeded in 12-well plates at a density of 5–8 × 104 per well. After 24 h, the cells were treated
with DOPE-PEI complexes or MNPs containing either siMDR-1 or a scramble siRNA
(siNegative). All formulations were prepared at an N/P of 16. The final concentration of
siRNA was 100 nM. After 4 h of incubation, the treatments were removed and cells were
reincubated for 48 h. Cells were then incubated for 1 h with doxorubicin (5 µg/ml). After
incubation, suspended cells were washed, trypsinized and fixed in a 4% formalin–
phosphate-buffered solution. Accumulation of intracellular doxorubicin was analyzed by
flow cytometry.
Cytotoxicity assays—The effect of P-gp silencing on doxorubicin toxicity was studied in
MCF-7 resistant and sensitive cells. Cells were seeded in 96-well plates at 3000 cells/well.
After 24 h, the cells were treated with siRNA (siMDR-1 or siNegative) formulations for 4 h.
Doxorubicin (1 µg/ml) was added 48 h post-siRNA. Control cells were treated with only
doxorubicin. Cell viability was measured after 24, 48, 72 and 96 h of doxorubicin incubation
with the CellTiter-Blue® (Promega). Briefly, 20 µl of CellTiter Blue was added to 100 µl
each well, and the plates were reincubated for 2 h. The fluorescence was measured at the
excitation and emission wavelength of 560 and 590 nm, respectively.
In a second set of experiments, the effect of the time lag between siRNA and doxorubicin
treatments on the drug toxicity was investigated in MCF-7 resistant cells. The cells were
seeded in 96-well plates at 3000 cells/well. After 24 h, the cells were treated with
formulations prepared with siMDR-1 and combined with doxorubicin (1 µg/ml) after 0, 4, 8,
24 and 48 h. Control cells were treated only with doxorubicin. The cell viability was
measured after 72 h of doxorubicin incubation with the CellTiter-Blue.
Statistical analysis—Results are presented as mean ± standard deviation, and statistical
significance of differences was evaluated by variance analysis, ANOVA; p-values smaller
than 0.05 were considered to indicate a significant difference.
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Results
Intracellular delivery of siRNA with DOPE-PEI complexes
It is well-known that the capacity of PEI to condense and protect siRNA can diminish if the
backbone of the polymer is grafted with lipid or PEG motifs [21,33,34]. Therefore, the first
step for the characterization of these novel conjugates was to assess their ability to bind
siRNA, form dense particles, and protect siRNA from enzymatic degradation
(Supplementary Figure 1, see online
www.futuremedicine.com/doi/suppl/10.2217/nnm.11.93). The DOPE-PEI conjugates
showed siRNA complexation similar to nonmodified PEI. The biophysical characterization
of DOPE-PEI complexes revealed particles ranging from 120 to 180 nm and with a positive
surface charge at N/P ≥3. Only complexes formed at a N/P ratio of 3 led to bigger particles,
less homogeneous in size and with negative zeta potential values. This increment in the
particle size when electroneutrality is reached has been reported for low-molecular-weight
PEI and other polymers [35,36]. DOPE-modified PEI protected siRNA from RNase III
degradation for at least 2 h. The quantification of the intact siRNA (ImageJ, NIH) revealed
that 92% of the condensed siRNA was recovered from DOPE-PEI complexes after the
enzymatic treatment.
The gene silencing efficacy mediated by DOPE-PEI complexes was studied with stably
GFP-expressing c166 cells (c166 GFP). In order to determine the optimal N/P ratio for the
maximum silencing activity, DOPE-PEI/siRNA complexes were prepared at varying N/P
ratios and evaluated for GFP downregulation. The silencing of GFP was measured by the
decrease in the mean fluorescence of c166 GFP cells after the treatment with complexes
prepared with GFP targeting siRNA. The lipid modification of PEI improved the silencing
efficacy of the polymer. Nonmodified PEI (1.8 kDa) gave no detectable GFP supression
regardless of the N/P employed (Figure 1A), whereas DOPE-PEI complexes showed a 2.5–
4-fold fluorescence decrease compared with control cells depending on the N/P used (Figure
1B). Formulations prepared with a scrambled siRNA did not decrease the cell fluorescence,
meaning that the decrease observed was due specifically to GFP downregulation. The
highest downregulation, an almost 75% reduction of GFP fluorescence, was achieved with
DOPE-PEI complexes prepared at a N/P ratio of 16. Silencing rate did not improve using
higher N/P ratios and remained constant up to a N/P of 30. Therefore, a N/P ratio of 16 was
selected for all further experiments.
Finally, a PEG/lipid coating was incorporated in the complexes. The hydrophobic
interactions between the lipid part of DOPE-PEI and the free lipids led to the formation of
MNPs, with small size and a neutral zeta potential. The incorporation of PEG and lipids
moderately increased the size of DOPE-PEI/siRNA complexes from 127 ± 2 to 178 ± 34 nm
in MNPs, while the zeta potential decreased from 22 ± 5 mV to a near neutral surface charge
(3 ± 1 mV). The effect of the PEG/lipid layer for MNPs silencing efficacy is shown in
Figure 2. The presence of PEG and lipids surrounding the DOPE-PEI/siRNA complexes
slightly decreased their silencing efficacy (Figure 2). Nevertheless, the ability of MNPs to
deliver siGFP into cells and suppress GFP expression was high enough and comparable to
that of Lipofectamine 2000 (positive control). The presence of a PEG coating, however,
made the preparation even less toxic. The absence of MNP toxicity previously reported by
[28,29] was confirmed for resistant and sensitive MCF-7 cells (Supplementary Figure 2,
black bars). Long-term toxicity was measured after a 4-h formulation treatment. PEG/lipid
coating of complexes improved long-term toxicity in MNPs and displayed approximately
100% cell viability compared with 50% viability for Lipofectamine complexes.
Navarro et al. Page 6
Nanomedicine (Lond). Author manuscript; available in PMC 2012 August 18.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
P-gp silencing with DOPE-PEI formulations
P-gp downregulation was evaluated in MCF-7-resistant cells using a siRNA targeting
MDR-1 gene (siMDR-1). The changes in P-gp surface protein expression were measured by
flow cytometry using a fluorescein isothiocyanate-labeled antibody, which recognizes an
external epitope of the P-gp protein. The overexpression of P-gp in control resistant cells
(nontreated with siMDR-1) was evident from a fluorescence increase in the presence of the
antibody (Figure 3A). This shift was not observed when the experiment was performed in
sensitive cells that have low basal levels of P-gp (Supplementary Figure 3).
DOPE-PEI complexes and MNPs effectively delivered siMDR-1 into in MCF-7 resistant
cells and significantly downregulated P-gp expression (Figure 3D & 3E, respectively).
siMDR-1 formulations (green histograms) showed less fluorescence than control cells (filled
histograms), meaning that less P-gp was expressed and presented on the cell surface. Thus,
less fluorescent antibody was attached. By contrast, those cells treated with siNegative
formulations (orange histograms) showed fluorescence similar to that of control cells. The
same results were obtained with Lipofectamine 2000 used as a positive control for siRNA
transfection (Figure 3F). No changes in P-gp expression were observed when the cells were
treated with free siMDR-1 or PEI complexes (Figure 3B & 3C, respectively).
Intracellular accumulation of doxorubicin
Intracellular doxorubicin was measured in MCF-7 cells to investigate whether the P-gp
silencing achieved by DOPE-PEI formulations could inhibit the drug efflux activity of the
transporter. Doxorubicin fluorescence increased approximately twofold in resistant cells
treated with DOPE-PEI or MNPs (Figure 4A). Treatment with formulations loading
nontargeted siRNA (siNegative) did not change the amount of drug inside the cells. This
latter finding confirms the specificity of the silencing and does not support drug
accumulation due to polymer permeabilization of cell membrane. As expected, the amount
of drug in sensitive cells was considerably higher compared with resistant cells (note the
different scales between Figure 4A & 4B). In sensitive cells, the intracellular doxorubicin
was not affected by the siRNA, siMDR-1 or siNegative (Figure 4B). At these experimental
conditions, the decrease of P-gp in the sensitive strain may not play a significant role in the
accumulation of the drug.
Cytotoxicity studies
Cytotoxicity studies were performed to probe the potential therapeutic usefulness of the
lipid–PEI system with different combinations of P-gp downregulation and doxorubicin to
overcome the MDR in (breast) cancer cells. The experiments were designed to gain insight
into how the P-gp downregulation and doxorubicin should be combined to exert their
maximum effect. First, siRNA and doxorubicin were sequentially administered with a time
lag of 48 h in order to maximize P-gp downregulation. Cell viability in resistant cells was
measured after different drug incubation times and compared with that in sensitive cells
(Figure 5). The pretreatment of resistant cells with either DOPE-PEI complexes or MNPs-
loaded siMDR-1 improved doxorubicin cytotoxicity. Significant differences (p < 0.001)
compared with drug-only treated cells were observed at all incubation time-points (Figure
5A). After 1 day of drug treatment, 95% of control resistant cells were viable. However,
cells treated with siMDR-1 formulations had cell viability of 45 and 65%, respectively, for
complexes and MNPs. After 2–3 additional days of drug treatment, the viability of
siMDR-1-treated cells dropped to 16% compared with 40% for drug-only control cells.
For sensitive cells, a significant improvement of drug efficacy was detected only for DOPE-
based complexes after 24 h of doxorubicin treatment. The toxicity profiles of the treatments
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were similar and did not improve with longer incubation times (Figure 5B). The inherent
sensitivity of the MCF-7 wild strain to doxorubicin may explain these results.
A comparison of doxorubicin toxicity towards resistant and sensitive cells indicated that the
combination of P-gp downregulation and doxorubicin can improve the therapeutic efficacy
of the drug against resistant cells to viability values similar to those for sensitive cells
(Figure 5A & 5B). It is important to note that scrambled siRNA formulations, used as a
control for P-gp silencing specificity, did not improve the drug efficacy and led to less drug
toxicity than that of siMDR-1 formulations (white and hatched bars, Supplementary Figure
3).
In the second set of experiments, the effect of different time lags between siRNA and drug
administration on doxorubicin toxicity was studied. As shown in Figure 6, the effectiveness
of doxorubicin was significantly improved by P-gp downregulation mediated by DOPE-PEI
complexes regardless of the time lag, even including a simultaneous administration (time
lag: 0 h; p < 0.001 vs doxorubicin only).
Discussion
Recent studies have shown that silencing of the MDR-1/P-gp gene using siRNA can
improve the effectiveness of anticancer drugs on MDR tumors [22,25,37,38]. In the case of
breast cancer, the wide availability of in vitro models and clinical data make this strategy
even more attractive [39]. However, two main problems need to be resolved. The first is
related to the inherent instability of siRNA that requires its association with viral or
synthetic carriers. The development of an ‘ideal delivery system’, highly efficient, nontoxic
and nonimmunogenic is still a major challenge. The second problem concerns the
optimization of the combination of P-gp silencing and the anticancer drug administration for
maximal therapeutic synergy. Some authors have shown that the sequential administration
of siRNA/drug permits a sufficient time to achieve substantial downregulation of P-gp and,
consequently, the maximum cell killing when the drug is administered to the cells [38,40].
By contrast, other authors suggested that the combination of drug and siRNA in a single
carrier could promote the synergy of the treatments by temporally colocalizing them in the
tumor cells [32,41,42]. In any case, it is desirable that a versatile carrier could fit different
administration schedules.
With this in mind, we synthesized and evaluated a novel phospholipid-PEI conjugate for
siRNA delivery and toxicity. These new conjugates were tested for P-gp silencing and
combined sequentially or simultaneously with doxorubicin to overcome MDR in breast
cancer cells.
The conjugate was prepared by coupling low-molecular-weight PEI (1.8 kDa) with DOPE
phospholipid. PEI 1.8 kDa has a low molecular weight and a small number of superficial
primary amines, which decreases its toxicity but also its transfection efficacy. The
conjugation of DOPE did not diminish siRNA condensation capacity of PEI. Small
complexes (<200 nm) were spontaneously formed when siRNA was mixed with DOPE-
modified PEI. Importantly, however, the silencing efficacy of PEI was dramatically
improved by DOPE conjugation. A wide range of N/P ratios (DOPE-PEI/siRNA or PEI/
siRNA) was tested for GFP silencing and the benefits of DOPE modification were clearly
shown for all (Figure 1). The absence of the GFP suppression observed for nonmodified PEI
turned into a 40–75% GFP signal reduction for DOPE-modified PEI depending on the N/P
ratio employed. This great improvement can be attributed to the DOPE acyl chains exposed
in the outer-shell of complexes. DOPE is frequently used in gene delivery as a helper lipid to
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promote the fusion of the carrier with the cell membrane and facilitate the disruption of
endosomes after the uptake of the complexes [43–45].
DOPE-PEI complexes were formulated in MNPs for improved biocompatibility. The lipid
moiety of DOPE-PEI can hydrophobically interact with PEG-PE and free lipids to self-
assemble into MNPs. We previously reported that MNPs had reduced cytotoxicity and
improved in vivo stability compared with plain PEI complexes [28,29]. Here, the benefits of
MNP formation were also demonstrated for DOPE-PEI complexes as MNP core. The
positive surface charge of DOPE-PEI complexes (22 ± 5 mV) decreased in MNPs to an
almost neutral and more biocompatible one (3 ± 1 mV). At the same time, the presence of
PEG surrounding DOPE-PEI complexes did not significantly influence the silencing
efficacy of MNPs but considerably decreased their cytotoxicity compared with
Lipofectamine 2000 or noncoated complexes, especially in sensitive MCF-7 cells. MNPs
should provide a useful platform for future in vivo targeted siRNA applications.
DOPE-PEI formulations were tested for P-gp silencing. The presence of P-gp on the surface
of resistant cells decreased after treating cells with DOPE-PEI or MNPs loaded siMDR-1.
This P-gp downregulation was translated into an effective inhibition of the drug efflux
activity. The amount of doxorubicin inside MDR-1-treated cells doubled that for control
cells. It is important to note that the reduction of P-gp expression and augmentation of drug
accumulation do not necessarily correlate with a complete reversion of MDR phenotype
[25,41]. In our case, P-gp downregulation mediated by DOPE-PEI and MNPs significantly
improved doxorubicin toxicity in resistant cells (Figure 5). Pretreatment of resistant cells
with siMDR-1 formulations before administration of doxorubicin, led to a twofold drop in
cell viability, similar to values in sensitive cells. Interestingly, the combination of
doxorubicin with DOPE-PEI complexes or MNPs led to somewhat different toxicity patterns
in resistant cells depending on the drug incubation time. After 24–48 h of incubation with
doxorubicin, MNPs showed lower cell kill values than DOPE-PEI complexes. At longer
drug incubation times, the toxicity profiles of DOPE-PEI complexes and MNPs became
similar. One possible explanation is that the PEG/lipid coating in MNPs may influence their
uptake and intracellular stability and ultimately interfere with the siRNA release process in
the cytoplasm. Differences in the silencing efficacy of PEG-coated (MNPs) and uncoated
DOPE-PEI complexes were observed in the initial characterization of DOPE formulations
using GFP silencing siRNA (Figure 2).
Most of the studies that focused on the combined use of P-gp siRNA and anticancer drugs
(doxorubicin and paclitaxel) reported successful results using a time lag of 24–48 h between
treatments. Yadav and collaborators studied the effect of separation duration (from 1 to 48
h) between siRNA and paclitaxel formulated in biodegradable nanoparticles. A significant
enhancement in cytotoxicity was observed only in resistant ovarian cancer cells when
paclitaxel was administered after 24 h of P-gp silencing [38]. Similarly, separated
preparations of cationic liposomes of siRNA and doxorubicin showed a therapeutic
improvement in mice but resulted in severe aggregation and doxorubicin leakage when
coencapsulated [40]. In this sense, one of the advantages of DOPE-PEI is that the
effectiveness of doxorubicin was improved regardless of the time lag between siRNA
formulation and drug, including the case of simultaneous administration of the treatments
(Figures 5 & 6).
Conclusion
We have demonstrated the feasibility and effectiveness of DOPE-PEI formulations to
deliver siRNA and modulate the expression of P-gp. The downregulation of P-gp translated
into an effective inhibition of the doxorubicin efflux activity, enhancement of intracellular
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doxorubicin accumulation and significant increase of drug toxicity in resistant human breast
cancer cells.
Future perspective
The development of effective and safe siRNA carriers suitable for systemic application is a
key step for future advances in cancer treatment with RNAi therapeutics. The phospholipid-
PEI nanocarriers developed in this study have demonstrated an excellent performance in
various cell lines (high silencing efficacy and low toxicity) and optimal biophysical
properties for systemic application (small size, nuclease stability). All these features together
with our previous results for DNA delivery in tumor-bearing mice suggests promising
results for the in vivo systemic application of these novel siRNA carriers.
Additionally, the amphiphilic structure of the DOPE-PEI conjugates provides high
flexibility to the system. The cationic polymeric part of the conjugate can condense and
protect different types of negatively charged nucleotides (plasmid, siRNA, oligonucleotide),
thereby opening new therapeutic opportunities. Similarly, the lipid graft permits the
interaction with PEG and lipids, as in the case of MNPs, for prolonged blood circulation, but
also permits the inclusion of other functional elements like cell-penetrating peptides or
antibodies for enhanced and tumor-targeted delivery.
The use of a siRNA silencing approach to solve some of the limitations of traditional
chemotherapy is gathering increased research interest. However, little is known about how
the different biophysical properties and mechanisms of action of the anticancer drug and the
siRNA will impact on their biodistribution and efficacy. In addition, the optimal dosage for
a siRNA/drug combination to exert its maximal in vivo effect has not been fully elucidated.
We have probed the potential therapeutic application of the lipid-PEI system with different
combinations of P-gp silencing and anticancer drugs to overcome MDR in breast cancer
cells. The in vivo evaluation of such systems after systemic administration using different
dosage schedules should be a priority task for future advances.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Executive summary
Background
▪ We have synthesized a novel conjugate between a phospholipid
(dioleoylphosphatidylethanolamine [DOPE]) and polyethylenimine (PEI), for
siRNA delivery for the purpose of silencing P-glycoprotein (P-gp) to
overcome doxorubicin resistance in MCF-7 human breast cancer cells.
DOPE-PEI formulations are effective & feasible siRNA carriers
▪ The novel conjugates self-assembled in the presence of siRNA into 120-nm
diameter particles with a positive zeta potential. DOPE-PEI complexes
protected siRNA from enzymatic degradation.
▪ Phospholipid conjugation dramatically improved the silencing efficacy of
PEI. The absence of green fluorescent protein suppression observed for
nonmodified PEI complexes, resulted in a 75% green fluorescent protein
signal reduction with DOPE-modified PEI complexes.
▪ Polyethylene glycol/lipid coating of the DOPE-PEI complexes gave rise to
micelle-like nanoparticles with better biocompatibility properties, including a
neutral surface charge and absence of cytotoxicity.
DOPE-PEI formulations mediate P-gp downregulation
▪ DOPE-PEI complexes and micelle-like nanoparticles effectively delivered
specific siRNA into in MCF-7 resistant cells and downregulated P-gp
expression.
DOPE-PEI formulations enhance intracellular doxorubicin accumulation
▪ The downregulation of P-gp translated into effective inhibition of the efflux
activity of the transporter. The amount of drug inside the cells doubled that of
non-siRNA-treated cells.
Combination of P-gp silencing by DOPE-PEI formulations & doxorubicin
overcomes multidrug resistance in breast cancer cells
▪ P-gp silencing mediated by DOPE-PEI and micelle-like nanoparticles
significantly increased the doxorubicin toxicity in resistant cells. This
improvement of chemotherapeutic efficiency was observed when P-gp
silencing siRNA and doxorubicin were administered separately or as
cotherapy.
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Figure 1. Green fluorescent protein downregulation by siRNA formulations in c166-green
fluorescent protein cells
(A) With PEI 1.8-kDa complexes and (B) DOPE-PEI complexes. c166-GFP cells (stably
expressing GFP) were treated with the formulations prepared with GFP-targeted siRNA (n =
3) or nontargeted siRNA (n = 1) at different N/P ratios. The siRNA concentration was 100
nM. After 4 h of incubation, complexes were removed and cells were incubated for 48 h.
Cells were trypsinized and analyzed by flow cytometry. The downregulation of GFP was
measured by the decrease in the mean fluorescence of the treated cells compared with
nontreated and expressed as a percentage of nontreated control cells.
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DOPE: Dioleoylphosphatidylethanolamine; GFP: Green fluorescent protein; N/P:
Polyethylenimine nitrogen/nucleic acid phosphate; PEI: Polyethylenimine.
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Figure 2. Effect of polyethylene glycol/lipid layer in micelle-like nanoparticles silencing efficacy
c166-GFP cells (stably expressing GFP) were treated with the formulations prepared with
GFP-targeted siRNA or nontargeted siRNA at PEI nitrogen/nucleic acid phosphate ratio of
16. The siRNA concentration was 100 nM. After 4 h of incubation, complexes were
removed and cells were incubated for 48 h. Cells were trypsinized and analyzed by flow
cytometry. The downregulation of GFP was measured by the decrease in the mean
fluorescence of the treated cells compared with nontreated and expressed as a percentage of
nontreated control cells. Data are expressed as the mean ± standard deviation (n = 3).
DOPE: Dioleoylphosphatidylethanolamine; GFP: Green fluorescent protein; MNP: Micelle-
like nanoparticle; PEI: Polyethylenimine.
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Figure 3. Decrease in the P-glycoprotein expression in resistant MCF-7 cells mediated by
phosphoethanolamine-polyethylenimine complexes and micelle-like nanoparticles
MCF-7 resistant cells were treated with different formulations prepared either with siMDR-1
or siNegative. After 4 h, the treatments were removed and fresh medium was added. The
cells were reincubated for 48 h. The cells were detached by mechanical scrapping,
resuspended in 0.5% bovine serum albumin, incubated with fluorescein isothiocyanate-
labeled antibody against P-gp and analyzed by flow cytometry. Filled histograms correspond
to nontreated cells (black, in the absence of antibody and blue in the presence of antibody),
green histograms correspond to formulations prepared with siRNA targeting MDR-1 and
orange histograms correspond to formulations prepared with scramble siRNA. A shift to the
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left is indicative of P-gp downregulation. The downregulation of P-gp was quantified by the
decrease in mean fluorescence of the treated cells and expressed as a percentage of P-gp
positive cells. Data are expressed as the mean ± standard deviation (n = 3).
*p < 0.05 versus control cells in the presence of antibody.
Ab: Antibody; MDR: Multiple drug resistance; MNP: Micelle-like nanoparticle; P-gp: P-
glycoprotein; PEI: Polyethylenimine; siNegative: Scrambled siRNA; siMDR: siRNA
targeting MDR-1.
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Figure 4. Intracellular doxorubicin levels
In (A) resistant and (B) sensitive MCF-7 cells mediated by DOPE-PEI complexes and
MNPs. MCF-7 resistant and sensitive cells were treated with formulations prepared either
with siRNA targeting MDR-1 or scramble siRNA. Control cells were treated only with
medium. After 4 h, medium was exchanged. Cells were reincubated for 48 h. Cells were
then treated for 1 h with doxorubicin (5 µg/ml), then washed, trypsinized and analyzed by
flow cytometry. The accumulation of doxorubicin within the cells was measured by the
increase in the mean fluorescence. Note ordinate scale differences. Data are expressed as the
mean ± standard deviation (n = 3).
*p < 0.001 versus Doxalone.
DOPE: Dioleoylphosphatidylethanolamine; Dox: Doxorubicin; MNP: Micelle-like
nanoparticle; PEI: Polyethylenimine; siNegative: Scrambled siRNA; siMDR: siRNA
targeting MDR.
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Figure 5. Doxorubicin cytotoxicity
In (A) resistant and (B) sensitive MCF-7 cells after treatment with DOPE-PEI complexes or
MNPs. MCF-7 resistant and sensitive cells were treated with formulations prepared with
siMDR-1. Control cells were treated with medium. After 4 h, the media was exchanged.
Cells were reincubated for 48 h. Cells were treated with doxorubicin (1 µg/ml) for 24, 48, 72
and 96 h and viability was measured. Data are expressed as the mean ± standard deviation (n
= 3).
p < 0.001 for DOPE-PEI treatments versus drug only treated cells for all time-points in
resistant cells.
DOPE: Dioleoylphosphatidylethanolamine; MNP: Micelle-like nanoparticle; PEI:
Polyethylenimine; siMDR-1: siRNA targeting MDR-1.
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Figure 6. Doxorubicin cytotoxicity in resistant MCF-7 cells after treatment with
phosphoethanolamine-polyethylenimine complexes at different time lags (h)
MCF-7 resistant and sensitive cells were treated with formulations prepared with siRNA
targeting MDR-1 (siMDR-1). Control cells were treated with medium. At different time
points post-siMDR-1, cells were treated with doxorubicin (1 µg/ml) for 72 h, and viability
was measured. Data are expressed as the mean ± standard deviation (n = 3). p < 0.001 for
dioleoylphosphatidylethanolamine-polyethylenimine treatments versus Dox-only treated
cells, for all time-points.
Dox: Doxorubicin.
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